

Invitation to Presentation of Herantis Pharma's 2H and Full Year Report 2021

Herantis Pharma Plc, Press Release, 7 February 2022 at 09:00 EET

Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson's disease, announced today that the company will report 2H and Full Year report 2021 and hold a live webinar (in English) for investors, analysts and media on:

Thursday, March 3rd, 2022, at 10:00 EET / 9:00 CET.

Herantis will publish the company's 2H and Full Year 2021 report on March 3, 2022, at 8:00 EET /7:00 CET.

The management will present Herantis and comment on the 2H and Full Year 2021 Report followed by a live Q&A session. Please join the webinar a few minutes in advance.

Please register for Herantis Pharma's 2H and FY 2021 Report Webinar

Link to Registration: [Herantis' FY 2021 Report Webinar](#)

After registering, you will receive a confirmation email containing information about joining the webinar.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying, CDNF-based therapies for Parkinson's disease that aim to restore proteostasis, body's natural neuronal protective mechanism. A failure in proteostasis results in pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated in the development of neurodegenerative diseases such as Parkinson's and Alzheimer's disease. CDNF is a protein that occurs naturally in the body. Its role is to protect neurons by balancing proteostasis, thereby preventing and counteracting disease generating mechanisms.

Herantis molecules in development are CDFN-based; HER-096 (a synthetic peptide) and rhCDFN (a biological protein). HER-096 and rhCDFN have both demonstrated to have a multimodal mechanism of action mimicking CDFN and to improve functional recovery of damaged neurons in preclinical models. Importantly, HER-096 has been shown to readily penetrate the blood brain barrier allowing for convenient subcutaneous dosing. Thanks to their multimodal mechanism of action, Herantis' molecules have the potential to stop the progression of Parkinson's disease and significantly improve patients' quality of life.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit <https://www.herantis.com>